知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.025 秒)

    TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS
    4.
    发明申请
    TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS 审中-公开
    TOLL-LIKE受体-7和-8调节性1H缩水甘油衍生化合物

    公开(公告)号：US20170029421A1

    公开(公告)日：2017-02-02

    申请号：US15230708

    申请日：2016-08-08

    申请人： The University of Kansas

    发明人： Sunil A. David ,  Nikunj M. Shukla

    IPC分类号： C07D471/04 ,  C07H15/26 ,  C07D519/00 ,  C07F5/02

    CPC分类号： C07D471/04 ,  A61K39/385 ,  A61K39/39 ,  C07D495/04 ,  C07D519/00 ,  C07F5/022 ,  C07F5/025 ,  C07H15/26 ,  C07K17/02 ,  C08B37/00 ,  G01N21/64 ,  G01N33/53

    摘要： The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.

    摘要翻译： 本公开提供了新的咪唑并喹啉衍生的化合物，其衍生物，其类似物及其药学上可接受的盐，以及制备和使用这些化合物的方法。 本公开还提供TLR7激动剂和TLR7 / TLR8双重激动剂，探针，组织特异性分子，佐剂，免疫原性组合物，治疗组合物和自我佐剂疫苗，包括咪唑并喹啉衍生的化合物，其衍生物，其类似物和药学上可接受的盐 其中。 咪唑并喹啉衍生化合物的衍生物还包括咪唑并喹啉衍生化合物的树枝状大分子和二聚体，以及制备和使用树枝状和二聚咪唑并喹啉衍生化合物的方法。 本公开还提供了包含本发明的咪唑并喹啉衍生化合物的双重TLR2 / TLR7混合激动剂。

    Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
    5.
    发明授权
    Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds 有权
    Toll样受体-7和-8调节性1H咪唑并喹啉衍生化合物

    公开(公告)号：US09441005B2

    公开(公告)日：2016-09-13

    申请号：US14279416

    申请日：2014-05-16

    申请人： The University of Kansas

    发明人： Sunil A. David ,  Nikunj M. Shukla

    IPC分类号： C07H15/26 ,  C07D471/04 ,  C07D495/04 ,  C07D519/00 ,  C07F5/02

    CPC分类号： C07D471/04 ,  A61K39/385 ,  A61K39/39 ,  C07D495/04 ,  C07D519/00 ,  C07F5/022 ,  C07F5/025 ,  C07H15/26 ,  C07K17/02 ,  C08B37/00 ,  G01N21/64 ,  G01N33/53

    摘要： The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.

    摘要翻译： 本公开提供了新的咪唑并喹啉衍生的化合物，其衍生物，其类似物及其药学上可接受的盐，以及制备和使用这些化合物的方法。 本公开还提供TLR7激动剂和TLR7 / TLR8双重激动剂，探针，组织特异性分子，佐剂，免疫原性组合物，治疗组合物和自我佐剂疫苗，包括咪唑并喹啉衍生的化合物，其衍生物，其类似物和药学上可接受的盐 其中。 咪唑并喹啉衍生化合物的衍生物还包括咪唑并喹啉衍生化合物的树枝状大分子和二聚体，以及制备和使用树枝状和二聚咪唑并喹啉衍生化合物的方法。 本公开还提供了包含本发明的咪唑并喹啉衍生化合物的双重TLR2 / TLR7混合激动剂。

    Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
    6.
    发明授权
    Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds 有权

    公开(公告)号：US10208037B2

    公开(公告)日：2019-02-19

    申请号：US15848349

    申请日：2017-12-20

    申请人： The University of Kansas

    发明人： Sunil A. David ,  Nikunj M. Shukla

    IPC分类号： C07D471/04 ,  C07D519/00 ,  C07D495/04 ,  C07F5/02 ,  C07H15/26 ,  A61K39/385 ,  A61K39/39 ,  C07K17/02 ,  C08B37/00 ,  G01N21/64 ,  G01N33/53

    摘要： The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeric and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.

    TOLL-LIKE RECEPTOR 2-AGONISTIC LIPOPEPTIDES, AND METHOD OF MAKING THE SAME
    8.
    发明申请
    TOLL-LIKE RECEPTOR 2-AGONISTIC LIPOPEPTIDES, AND METHOD OF MAKING THE SAME 有权
    类似感受器2激动剂的类似受体及其制备方法

    公开(公告)号：US20150337009A1

    公开(公告)日：2015-11-26

    申请号：US14761805

    申请日：2014-01-17

    申请人： UNIVERSITY OF KANSAS

    发明人： Deepak B. Salunke ,  Xiaoqiang Guo ,  Sunil A. David

    IPC分类号： C07K5/068 ,  A61K39/39

    CPC分类号： C07K5/06086 ,  A61K38/00 ,  A61K39/39 ,  A61K2039/55516 ,  C07K5/0606 ,  C07K14/705

    摘要： The present disclosure is directed to a novel class of toll-like receptor 2-agonistic (TLR2) lipopeptide compounds having specific structures, and synthetic methods of making the compounds. These compounds provide high potency of agonistic activities with human, other than murine, TLR2, and are useful as vaccine adjuvants. Vaccines are perhaps one of the most successful medical interventions against infectious disease.

    摘要翻译： 本公开涉及具有特定结构的新一类类型的toll样受体2-激动（TLR2）脂肽化合物，以及制备该化合物的合成方法。 这些化合物与除了鼠TLR2以外的人具有很强的激动活性，并且可用作疫苗佐剂。 疫苗可能是抗传染病最成功的医疗措施之一。